admin

Next year marks the 40th anniversary of the passage of the Bayh-Dole Act. With election day looming, 2020 is likely to be the most politically contentious year of our lifetime. The country is divided right down the middle on many fundamental issues. Rather than debate, the opposing sides often descend into personal attacks, even questioning one another’s patriotism. This isn’t the time you want issues you care about dragged into the public arena, but patent rights and the Bayh-Dole Act have been summoned into the gladiator pit. Happy birthday, indeed.

GAITHERSBURG, Md., Oct. 24, 2019 /PRNewswire/ — MaxCyte, the global cell-based therapies and life sciences company, announces today that, having completed dosing of the second cohort of patients, clinical investigators have initiated dosing in the third cohort of patients of MaxCyte’s Phase I clinical trial with the next higher cell dose of MCY-M11. This lead, wholly-owned, non-viral mRNA-based cell therapy candidate from MaxCyte’s CARMA platform is a mesothelin-targeting chimeric antigen receptor (CAR) therapy being tested in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

The Montgomery County Business Hall of Fame (MCBHOF) is excited to announce Dr. Robert Caret as the keynote speaker for its annual luncheon and induction ceremony on October 29.

Dr. Caret is the Chancellor of the University System of Maryland. He has held this position since 2015 where he established the priorities of access and affordability, college completion, academic and research excellence, and workforce development. Under his leadership, the USM has expanded partnerships with the business community and embraced a more entrepreneurial approach, positioning the system as vital economic and workforce engine for Maryland.

With its world-class institutions, talent and collaboration, now is the time for Maryland to take the next steps in becoming the nation’s premier science and tech-based innovation and entrepreneurial corridor.

Pocket-size ultrasound devices that cost 50 times less than the machines in hospitals (and connect to your phone). Virtual reality that speeds healing in rehab. Artificial intelligence that’s better than medical experts at spotting lung tumors. These are just some of the innovations now transforming medicine at a remarkable pace.

Although touted as having potential to cure some of the most intractable of human illnesses, gene therapies also carry some eye-popping price tags that have threatened to limit their availability to wealthy countries. However, a new public-private partnership aims to make them available to people around the world, including in developing countries.

NEW YORK, Oct. 25, 2019 /PRNewswire/ — The Prix Galien USA Committee last night honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 13th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. In recognition of the development and discovery of products that improve the human condition, a committee of highly accomplished scientific leaders, inclusive of four Nobel Laureates, recognized winners in three categories: “Best Pharmaceutical Product,” “Best Biotechnology Product,” and “Best Medical Technology.”

Image: “Best Pharmaceutical Product:” GlaxoSmithKline, SHINGRIX

BALTIMORE, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) — CoapTech LLC announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded the company a two-year, $1.2M R44 Small Business Innovation Research (SBIR) Phase II grant on August 29, 2019. This builds on a $225,000 Phase I SBIR R43 grant and a $200,000 Maryland Industrial Partnerships (MIPS) grant awarded to the company last year.  

The new $1.2M grant will support a 40-patient clinical trial at the University of Maryland Medical Center (UMMC) evaluating safety and cost-effectiveness characteristics of a novel medical procedure known as percutaneous ultrasound gastrostomy (PUG), which is enabled by CoapTech’s PUMA-G device.